Search

Your search keyword '"Jarolim, Petr"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Jarolim, Petr" Remove constraint Author: "Jarolim, Petr" Database Complementary Index Remove constraint Database: Complementary Index
112 results on '"Jarolim, Petr"'

Search Results

2. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

3. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response.

4. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.

5. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.

6. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.

7. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.

8. Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022.

9. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.

10. A polygenic risk score predicts atrial fibrillation in cardiovascular disease.

12. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies.

13. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF).

14. Hemolysis Index and Potassium Reporting.

15. A Potassium-Based Quality-of-Service Metric Reduces Phlebotomy Errors, Resulting in Improved Patient Safety and Decreased Cost.

16. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.

17. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.

18. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.

19. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

20. Evaluation of Three Commercial and Two Non-Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2.

21. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58.

23. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.

24. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.

25. The effect of three major co‐morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction.

29. Racial/ethnic differences in circulating natriuretic peptide levels: The Diabetes Prevention Program.

30. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

32. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.

34. Clinical and Humoral Determinants of Congestion in Heart Failure: Potential Role of Adiponectin.

36. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS.

38. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

42. Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients.

43. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.

48. A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum.

50. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers.

Catalog

Books, media, physical & digital resources